CA3134085A1 - Osmotic pressure regulator for peritoneal dialysate containing d-allose and/or d-allulose - Google Patents

Osmotic pressure regulator for peritoneal dialysate containing d-allose and/or d-allulose Download PDF

Info

Publication number
CA3134085A1
CA3134085A1 CA3134085A CA3134085A CA3134085A1 CA 3134085 A1 CA3134085 A1 CA 3134085A1 CA 3134085 A CA3134085 A CA 3134085A CA 3134085 A CA3134085 A CA 3134085A CA 3134085 A1 CA3134085 A1 CA 3134085A1
Authority
CA
Canada
Prior art keywords
glucose
allose
dialysate
peritoneal
allulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3134085A
Other languages
English (en)
French (fr)
Inventor
Tetsuo Minamino
Taro Ozaki
Akihide YOSHIHARA
Ken Izumori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kagawa University NUC
SETOLAS Holdings Inc
Original Assignee
Kagawa University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kagawa University NUC filed Critical Kagawa University NUC
Publication of CA3134085A1 publication Critical patent/CA3134085A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
CA3134085A 2019-03-29 2020-03-10 Osmotic pressure regulator for peritoneal dialysate containing d-allose and/or d-allulose Pending CA3134085A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-065393 2019-03-29
JP2019065393 2019-03-29
PCT/JP2020/010232 WO2020203086A1 (ja) 2019-03-29 2020-03-10 Ｄ－アロースおよび／またはｄ－アルロースを含有してなる腹膜透析液の浸透圧調整剤

Publications (1)

Publication Number Publication Date
CA3134085A1 true CA3134085A1 (en) 2020-10-08

Family

ID=72668623

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3134085A Pending CA3134085A1 (en) 2019-03-29 2020-03-10 Osmotic pressure regulator for peritoneal dialysate containing d-allose and/or d-allulose

Country Status (7)

Country Link
US (1) US20220175931A1 (https=)
EP (1) EP3950057A4 (https=)
JP (1) JPWO2020203086A1 (https=)
CN (1) CN113710317A (https=)
BR (1) BR112021016283A2 (https=)
CA (1) CA3134085A1 (https=)
WO (1) WO2020203086A1 (https=)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4943839B1 (https=) 1968-06-10 1974-11-25
JPS5330976B1 (https=) 1971-07-22 1978-08-30
JPS5317055B2 (https=) 1972-08-09 1978-06-06
US3991349A (en) 1975-01-03 1976-11-09 Westinghouse Electric Corporation Droop adjustable control apparatus for direct current motor drives
JPS5316164A (en) 1976-07-27 1978-02-14 Aisin Seiki Co Ltd Fluid coupling device
JPS589701B2 (ja) 1977-06-04 1983-02-22 株式会社栗本鉄工所 廃棄物処理装置
JPH1171273A (ja) 1997-08-29 1999-03-16 Terumo Corp 腹膜透析液
JP4473980B2 (ja) 1999-06-24 2010-06-02 株式会社林原生物化学研究所 糖質複合体結晶とその製造方法
JP4499882B2 (ja) 2000-07-07 2010-07-07 株式会社林原生物化学研究所 Ｄ−キシロース・イソメラーゼを用いるアルドヘキソースの製造方法
JP4882054B2 (ja) 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
CN1668735A (zh) * 2002-05-22 2005-09-14 国立大学法人香川大学 稀有糖的生物活性的利用方法及配合了稀有糖的组合物
JP2005102503A (ja) 2003-01-10 2005-04-21 Kagawa Univ 新しい触媒機能を有するｌ−ラムノースイソメラーゼの遺伝子配列およびその用途
JP5421512B2 (ja) * 2004-01-30 2014-02-19 帝國製薬株式会社 Ｄ−プシコースの血糖上昇抑制効果の利用
JP4724824B2 (ja) 2004-03-19 2011-07-13 国立大学法人 香川大学 希少糖のｔリンパ球の増殖抑制への使用
JP4888937B2 (ja) * 2004-05-24 2012-02-29 国立大学法人 香川大学 微生物増殖抑制への希少糖の使用
US7691619B2 (en) 2004-08-24 2010-04-06 Rare Sugar Production Technical Research Laboratories, Llc Sequence of thermotolerant L-rhamnose isomerase gene and use of the same
EP1864669B1 (en) 2005-03-23 2018-06-27 Rare Sugar Production Technical Research Laboratories, LLC Application of d-psicose to suppression of abnormal circadian increase in blood glucose level
KR100744479B1 (ko) 2005-06-01 2007-08-01 씨제이 주식회사 사이코스 에피머화 효소에 의한 사이코스의 생산 방법
JP5116072B2 (ja) * 2005-07-20 2013-01-09 帝國製薬株式会社 Ｄ−アロースの血糖上昇抑制効果の利用
US8440619B2 (en) 2005-08-31 2013-05-14 National University Corporation Kagawa University Utilization of hypertension/hypercardia-preventing effect of D-allose
JP2009269887A (ja) 2008-05-09 2009-11-19 Kagawa Univ 希少糖を含有する腹膜劣化抑制剤、腹膜透析液および腹膜透析法
WO2012011588A1 (ja) * 2010-07-23 2012-01-26 学校法人東海大学 腹膜透析患者用の経口医薬組成物及びその用法
AR086745A1 (es) * 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
JP5997693B2 (ja) 2011-07-06 2016-09-28 松谷化学工業株式会社 アルスロバクターグロビホルミスの生産する酵素

Also Published As

Publication number Publication date
JPWO2020203086A1 (https=) 2020-10-08
BR112021016283A2 (pt) 2021-10-13
CN113710317A (zh) 2021-11-26
EP3950057A4 (en) 2022-12-28
EP3950057A1 (en) 2022-02-09
US20220175931A1 (en) 2022-06-09
WO2020203086A1 (ja) 2020-10-08

Similar Documents

Publication Publication Date Title
KR0145289B1 (ko) 히스티딘 완충 복막 투석 용액
CN1163236C (zh) 用于连续性不卧床性腹膜透析的生物适合的水溶液
US5112865A (en) Pharmaceutical compositions containing a derivative of 3-hydroxybutanoic acid chosen from oligomers of this acid and esters of this acid or of these oligomers with 1,3-butanediol
US6492336B1 (en) Peritoneal dialysis fluid
US4879280A (en) Dialysis solution for use in intraperitoneal dialysis
JP5507609B2 (ja) 腹膜透析液
US5011826A (en) Aqueous dialysis and rinsing solution for intraperitoneal administration
AU587061B2 (en) Dialysic fluid
EP0078832B1 (en) Dialysis solution containing glycerol
JP4638106B2 (ja) 医薬的使用のための溶液中における浸透圧剤としての、ｌ−カルニチンおよびそのアルカノイル誘導体の使用
CN104622896A (zh) 一种钠钾镁钙葡萄糖注射液的制备方法
AU682609B2 (en) Dialysis fluid containing peptides obtained from casein as osmotic agents and bicarbonate ions as buffering agents
JP4766653B2 (ja) 眼科用医薬組成物
JP2009269887A (ja) 希少糖を含有する腹膜劣化抑制剤、腹膜透析液および腹膜透析法
US20130197428A1 (en) Peritoneal Dialysis Method
US20220175931A1 (en) Osmotic pressure regulator for peritoneal dialysate containing d-allose and/or d-allulose
JP5405736B2 (ja) 透析用水溶液
Shockley et al. New solutions for peritoneal dialysis in adult and pediatric patients
Misra et al. Peritoneal Dialysis in Diabetic End-Stage Kidney Disease
Misra et al. Peritoneal dialysis in diabetic end-stage renal disease
WO2002081005A2 (en) Peritoneal dialysis fluid
Coles Biocompatibility of various osmotic solutes
JPWO2010106871A1 (ja) 浸透圧調整剤
MXPA00001267A (en) Peritoneal dialysis fluid

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231204

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250116

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250127

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250127

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250512

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250512

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250717

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250717

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251027

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251202

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260106

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260106

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260204